Scholarlink

Objectives <p>Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer (BC), characterized by poor clinical behaviors and outcomes. <i>TMOD1</i> was reported as a downstream target of NF-κB contributing to the growth of cancer cells. However, it’s impacts on TNBC patients’ prognosis and treatment response remain unclear.</p> Methods <p>The prognostic value of <i>TMOD1</i> was analyzed by data from the Kaplan–Meier database and verified through immunohistochemical evaluation from 190 TNBC patients in West China Hospital (WCH). Cell Counting Kit-8 assay, Transwell cell migration assay and Matrigel invasion assay were used for in vitro study. TNBC cells treated with gradient dosage of doxorubicin (Dox), paclitaxel (PTX), and 5-fluorouracil (5-FU) for chemotherapy sensitivity assay. The chemotherapy sensitivity of Dox in vivo was further confirmed by cell line-derived xenograft (CDX) model.</p> Results <p>TNBC patients with high <i>TMOD1</i> expression had longer overall survival (OS) and recurrence-free survival (RFS) in both Kaplan–Meier plotter database and in cohort from WCH. In cellular functional study, overexpression of <i>TMOD1</i> promoted TNBC cells’ proliferation, migration and invasion. It also enhanced TNBC sensitivity to Dox treatment both in vivo and in vitro.</p> Conclusions <p>High <i>TMOD1</i> expression in TNBC patients is associated with better prognosis. Although <i>TMOD1</i> expression promotes TNBC cell proliferation, migration, and invasion, <i>TMOD1</i> enhances the sensitivity to Dox therapy both in <i>vivo</i> and in vitro, which might contribute to improve the prognosis for TNBC patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Tropomodulin 1 is essential for chemotherapy sensitivity and associated with better outcome in triple-negative breast cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月16日

查看全文
  • Yijie Li,
  • Xinyi Long,
  • Yiting Xie,
  • Xiaorong Zhong,
  • Shiyu Cao,
  • Fei Chen,
  • Mengjia Shen,
  • Lin Xiao,
  • Lijuan Yin,
  • Feng Ye,
  • Ting Luo

摘要

Objectives

Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer (BC), characterized by poor clinical behaviors and outcomes. TMOD1 was reported as a downstream target of NF-κB contributing to the growth of cancer cells. However, it’s impacts on TNBC patients’ prognosis and treatment response remain unclear.

Methods

The prognostic value of TMOD1 was analyzed by data from the Kaplan–Meier database and verified through immunohistochemical evaluation from 190 TNBC patients in West China Hospital (WCH). Cell Counting Kit-8 assay, Transwell cell migration assay and Matrigel invasion assay were used for in vitro study. TNBC cells treated with gradient dosage of doxorubicin (Dox), paclitaxel (PTX), and 5-fluorouracil (5-FU) for chemotherapy sensitivity assay. The chemotherapy sensitivity of Dox in vivo was further confirmed by cell line-derived xenograft (CDX) model.

Results

TNBC patients with high TMOD1 expression had longer overall survival (OS) and recurrence-free survival (RFS) in both Kaplan–Meier plotter database and in cohort from WCH. In cellular functional study, overexpression of TMOD1 promoted TNBC cells’ proliferation, migration and invasion. It also enhanced TNBC sensitivity to Dox treatment both in vivo and in vitro.

Conclusions

High TMOD1 expression in TNBC patients is associated with better prognosis. Although TMOD1 expression promotes TNBC cell proliferation, migration, and invasion, TMOD1 enhances the sensitivity to Dox therapy both in vivo and in vitro, which might contribute to improve the prognosis for TNBC patients.